Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non‐alcoholic fatty liver disease

BACKGROUND: Lipotoxicity leading to excessive caspase‐mediated apoptosis and inflammation is believed to drive liver damage in NAFLD. Emricasan is a pan‐caspase inhibitor that decreased serum ALT and apoptotic and inflammatory markers in subjects with chronic hepatitis. AIMS: To assess whether 28 da...

Cur síos iomlán

Na minha lista:
Sonraí Bibleagrafaíochta
Foilsithe in:Aliment Pharmacol Ther
Main Authors: Shiffman, Mitchell, Freilich, Bradley, Vuppalanchi, Raj, Watt, Kymberly, Chan, Jean L., Spada, Al, Hagerty, David T., Schiff, Eugene
Formáid: Artigo
Teanga:Inglês
Foilsithe: John Wiley and Sons Inc. 2018
Ábhair:
Randomised Clinical Trial
Rochtain Ar Líne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6587784/
https://ncbi.nlm.nih.gov/pubmed/30430605
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apt.15030
Clibeanna: Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!

Míreanna Comhchosúla